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Anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vas-
culitides (AAV) are characterized by systemic inﬂammation of small-
to medium-sized blood vessels [1]. A hallmark of AAV is the presence
of ANCA [2], predominantly directed against the enzymes proteinase 3dicine, Division of Nephrology,
lein 1, 9713 GZ Groningen, The
).
.V. This is an open access article und(PR3) [3] and myeloperoxidase (MPO) [4]. Both enzymes are stored in
both primary granules of neutrophils and lysosomes of monocytes and
are released into the extracellular environment upon cell activation
[5]. Based on clinical and histopathological features, AAV is divided
into three disease categories: granulomatosis with polyangiitis (GPA),
microscopic polyangiitis (MPA) and eosinophilic GPA (EGPA) [6]. GPA
is characterized by pauci-immune necrotizing granulomatous inﬂam-
mation, particularly in the upper airways and the kidneys [7,8]. In
MPA necrotizing vasculitis is also common, however, without granulo-
matous inﬂammation [8]. ANCA are most commonly directed against
PR3 [9] and MPO [10] in GPA and MPA respectively. In contrast to GPAer the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
414 A. von Borstel et al. / Autoimmunity Reviews 17 (2018) 413–421andMPA, EGPA is, in addition to small vessel vasculitis, typically charac-
terized by eosinophilia and asthma and is an infrequent AAV disease
type [6]. Because EGPA is histopathologically and clinically different
from GPA and MPA, this disease subtype will not be further discussed
in this review.
Although the pathogenesis of AAV has not been fully elucidated, the
pathogenic potential of ANCA in the early effector phase of the disease is
fairly well established (reviewed in [11]). The generally acceptedmech-
anism includes exposure of neutrophils to pro-inﬂammatory cytokines
(e.g. interleukin (IL)-1β and tumor necrosis factor (TNF)-α) causing
translocation of the ANCA-antigens (Ags) to the cell surface. Following
binding of ANCA, neutrophils are fully activated, resulting in the produc-
tion of reactive oxygen species and release of their granular contents,
which include the ANCA-Ags PR3 andMPO.More recently, an important
role for alternative complement pathway activation in the disease in-
duction has been established and C5a/C5a receptor interactions have
been demonstrated to be important primers of neutrophils for activa-
tion by ANCA (reviewed in [12]).
AAV are autoimmune diseases implicating a breach of tolerance to
self, but why autoimmunity to ANCA-Ags develops and why the im-
mune system fails to suppress autoreactive lymphocytes in these pa-
tients is unknown. In homeostasis, our immune system is well
balanced and regulatory mechanisms exist to dampen effector immune
responses to limit tissue damage andmaintain tolerance. Autoreactivity
usually does not lead to autoimmune disease since regulatory cells efﬁ-
ciently suppress the immune response against autoAgs. Failure of im-
mune suppression due to defects of regulatory immune cells might
thus cause a break in self-tolerance, leading to autoimmune disease.
Consequently, resolution of chronic inﬂammation often requires
immunosuppressive medication in order to regain control over the
autoreactive response [13]. Two immune regulatory cell types essential
for peripheral tolerance are regulatory T cells (Tregs) and regulatory B
cells (Bregs). Tregs were ﬁrst discovered by Sakaguchi and coworkers,
who showed that this T cell subsetwas critical in preventing autoimmu-
nity [14].More recently, immunosuppressive capacity has been demon-
strated in the B cell lineage as well and the existence of so-called Bregs
has been proposed [15].
In recent years, evidence has emerged that the delicate balance be-
tween immune effector responses and immune regulation in AAV is dis-
turbed and malfunctioning of immune regulatory cells in AAV patients
has been described. In this review, we will discuss the current knowl-
edge on the role of Tregs and Bregs in the AAV pathogenesis and how
aberrations in their immune regulatory properties might contribute to
disease progression.
2. T cell involvement in AAV
AAV is generally considered an autoantibody (autoAb)-mediated
disease due to the central role of ANCA in the effector phase of the dis-
ease. However, this does not exclude an important pathogenic role for T
cell responses in AAV as well. The onset of AAV is postulated to arise
from repeated exposure to an (super) Ag, resulting in persistent T cell
activation. Malfunctioning of the Treg compartment results in failure
to suppress the activation of autoAg-speciﬁc T cells [16]. Indeed, acti-
vated T cells can be readily detected in inﬂammatory lesions in the af-
fected organs of AAV patients, particularly in the granulomas, which
are a characteristic histopathological feature of GPA. Moreover, in AAV
patients alterations in circulating T cell subsets and increased levels of
soluble factors indicative of T cell activation in the serum have been de-
scribed [17–19]. For example, increased levels of soluble T cell activation
markers such as sCD25 and sCD30 can be detected in the plasma of GPA
patients when compared to healthy controls (HCs) [17]. Also, increased
numbers of persistently activated T cells (i.e. T cells with high HLA-DR
expression) are present in AAV patients and are positively associated
with disease severity [18,19]. This strongly suggests that the T cell com-
partment in AAV is in a persistently activated state.In GPA, the contribution of CD4+ T helper (Th) cells to the immune
pathologymight depend onwhether the disease is localized or general-
ized. Initially, research in GPA patients focused on the disturbed balance
between Th1 and Th2 cells. Studies revealed that CD4+ T cells of GPA
patients with active disease displayed a profound Th1 cytokine proﬁle,
characterized by increased interferon (IFN) γ production but normal
IL-4 production [20,21]. Subsequently it was found that Th1-
associated markers in the circulation and in nasal granulomatous
lesions dominate in patients with localized disease, while Th2-
associated markers are more prominent in patients with generalized
disease [22,23].More recently, it was demonstrated that in GPA patients
Ag-speciﬁc Th17 cells are expanded, irrespective of disease activity and
maintenance therapy [24]. In active GPA patients elevated serum IL-17
levels have been found [25], which remained elevated when patients
entered remission [26]. Moreover, in vitro stimulation of PBMCs from
GPA patients with PR3 resulted in increased IL-17 and RORγT (i.e. tran-
scription factor (TF) of Th17 cells) expression [25].
In summary, in AAV persistent T cell activation, especially of Th17
cells, is well established and likely contributes to the autoimmune path-
ogenesis of AAV. However, themechanisms that initiate andmaintain T
cell activation in AAV remain unclear. Interestingly, emerging evidence
indicates that in AAV Tregs do not function properly, suggesting that
disturbed immune regulation is an important factor in persistent T cell
activation in AAV. Following a brief introduction on Tregs and their
mechanisms of action, the existing evidence for Treg malfunctioning
in AAV will be discussed.
2.1. Regulatory T cells: Phenotype and mechanism of action
The immunosuppressive ability of T cells was ﬁrst discovered
N40 years ago [27,28]. However not until 1995, a subset of circulating
CD4+ Th cells characterized by the expression of the IL-2 receptor α-
chain (i.e. CD25) was identiﬁed and shown to be critical for the preven-
tion of autoimmunity [14]. Depletion of CD4+CD25+ T cells in wild type
(WT) mice and transfer of the remaining T cells into syngeneic athymic
nudemice induced autoimmunity andmulti-organ injury [14]. Interest-
ingly, transfer of the CD4+CD25+ T cell subset into the same mice
prevented the development of autoimmunity. Later, similar CD4+ sup-
pressor T cells or Tregs were also found in humans. In co-cultures of
CD4+CD25hi T cells with CD4+CD25− responder T cells, it was shown
that the CD4+CD25hi T cell subset was potent in directly suppressing
proliferation of and cytokine production by CD4+CD25− responder T
cells [29]. These results provided the ﬁrst evidence for the existence of
human Tregs and identiﬁed a phenotype whereby these cells can be
detected.
Subsequent research identiﬁed a key marker expressed in Tregs,
which distinguishes them from other CD4+ T cells: the TF FoxP3.
FoxP3 encodes the scurﬁn protein and was ﬁrst detected in the scurfy
mouse strain. These mice have X-linked recessive mutations in the
FoxP3 gene, leading to mortality of hemizygous male mice at the age
of 16–25 days. These hemizygousmalemice show excess lymphoprolif-
eration combined with inﬁltration of CD4+ T cells in multiple organs
that overproduce cytokines [30]. A mutated form of FoxP3 was later
also described in patients with X-linked syndrome (i.e. IPEX), a disease
characterized by immunodysregulation, polyendocrinopathy, and en-
teropathy [31–33]. Additional research in both scurfymice and IPEX pa-
tients showed that CD4+CD25+ Tregs were absent. Interestingly,
retroviral transduction of FoxP3 into naïve CD25−CD4+ T cells induced
T cells that phenotypically and functionally resembled potent Tregs
[34]. These results indicate that FoxP3 is necessary for both Treg devel-
opment and function. According to the expression level of FoxP3 in
naïve and memory CD4+ Th cells, different Treg subsets have been de-
scribed by Miyara and coworkers [35]. In total, three subpopulations
of FoxP3+CD4+ T cells in the peripheral blood of humans were identi-
ﬁed: CD45RA+FoxP3lo resting Tregs (rTregs), CD45RA−FoxP3hi acti-
vated Tregs (aTregs) and IFNγ- and IL-2-secreting Tregs that are
415A. von Borstel et al. / Autoimmunity Reviews 17 (2018) 413–421CD45RA−FoxP3loCD25+. The ﬁrst two Treg subpopulations (i.e. rTregs
and aTregs) had potent suppressive function in vitro, whereas
cytokine-secreting CD45RA−FoxP3loCD25+ Tregs did not suppress ef-
fector T cells [35]. This indicates that expression of FoxP3 alone is insuf-
ﬁcient to identify truly suppressive Tregs. Accordingly, different
isoforms of FoxP3 have been investigated in human Tregs [36]. The
ﬁrst isoform represents the full-length isoform, and the second repre-
sents an isoform lacking the exon 2. It has been shown that different
FoxP3-isoforms impact Treg function and lineage commitments. More
speciﬁcally, the full-length FoxP3 (FoxP3ﬂ), but not the isoforms lacking
exon 2 (FoxP3Δ2), interact with the Th17 TF RORγt and inhibit the ex-
pression of genes that deﬁne Th17 cells [37–39]. Interestingly, a recipro-
cal relationship in the development of Tregs and Th17 cells has been
described [40–42]. In line with this, it has been demonstrated that,
under neutral conditions in vitro, TGFβ can shift the balance towards
functional FoxP3+ Tregs, whereas in the context of an inﬂammatory cy-
tokinemilieu (i.e. IL-1β, IL-2, IL-15) functional Tregs convert into IL-17-
producing, non-functional Tregs. Thus, assessment of FoxP3-isoforms in
combination with the expression of CD25 and CD45RA are essential to
delineate the truly suppressive Tregs.
The exact mechanisms by which Tregs regulate immune responses
are not fully understood. It is assumed that these cells use different
mechanisms to exert their function, namely secretion of anti-
inﬂammatory cytokines, cytolysis,metabolic disruption andmodulationFig. 1.Overviewof immune suppressivemechanisms used by Tregs and Bregs. Bregs and Tregs i
IL-10, IL-35, TGFβ) and induce apoptosis of autoreactive cells via production of granzymes. Bregs
86-CTLA-4 interaction. Tregs can suppress autoreactive cells via CTLA4-CD80/86-mediated indu
can indirectly inhibit activated autoreactive cells via IL-2 deprivation or via transfer of soluble m
be enhanced by IL-10 secreted by Bregs. In AAV, aberrancies in both Tregs and Bregs contrib
diminished. Due to decreased (functional) IL-2R expression, less IL-2 can be bound mediat
autoreactive cells. Moreover, the relative ratio of the full length FoxP3 isoform (FoxP3ﬂ) over
commitments. Lower ratio of FoxP3ﬂ/FoxP3Δ2 isoforms will favor conversion of Tregs into IL-
lower Breg frequency was found in AAV, which seems so far the most important reason for deof dendritic cell (DC) maturation and/or function (reviewed in [43])
(Fig. 1). Tregs are potent producers of anti-inﬂammatory cytokines
such as IL-10, IL-35 and TGFβ, all of which can suppress responses of ac-
tivated immune cells (reviewed in [43]). Cytolysis is a mechanism in
which Tregs release enzymes that induce apoptosis of effector cells
(e.g. granzyme A or B). Tregs are equipped with a third mechanism,
namely metabolic disruption. An example of metabolic disruption by
Tregs is IL-2 deprivation that induces cell death in effector cells. Another
example is that Tregs can inhibit effector cell function via transfer of sol-
uble mediators (e.g. cyclic AMP) via gap junctions into target cells (e.g.
effector T cells and DCs) [43]. In target cells, cAMP induces inducible
cAMP early repressor (ICER), which is thought to inhibit cell prolifera-
tion and IL-2 production [44]. Lastly, Tregs canmodulate DCmaturation
and function via physical interaction through inhibitory surface mole-
cules such as lymphocyte activation gene (LAG) 3 and cytotoxic T
lymphocyte-associated Ag (CTLA)-4. When DCs sense these molecules,
production of indoleamine 2,3-dioxygenase (IDO) is initiated, which
in turn suppresses other immune cells [43]. The mechanism by which
Tregs initiate suppression is dependent on the Ag dose. A high Ag dose
elicits potent inhibition via induction of FAS-mediated apoptosis or T
cell receptor (TCR) ligation, which both result in T cell anergy, whereas
a low Ag dose only induces secretion of IL-10 or TGF-β [45]. Tregs can
prevent autoimmunity by inhibiting the activation of T effector cells
via both inhibitory co-stimulation and secretion of anti-inﬂammatorynhibit autoreactive cells and Th17 cells via production of anti-inﬂammatory cytokines (e.g.
also exert suppressive function via direct cell contactmediated via CD40-CD40L and CD80/
ction of IDO,which is an immune suppressivemolecule produced byDCs. In addition, Tregs
ediators (e.g. cyclic AMP) through gap junctions. The suppressive capacity of Treg cells can
ute to the disease pathogenesis. The suppressive function of Tregs in AAV seems to be
ing decreased suppressive cytokine production (i.e. IL-10, TGFβ and IL-35) that inhibit
the FoxP3 isoforms lacking the exon 2 (FoxP3Δ2) may impact Treg function and lineage
17-secreting cells, which may contribute to the AAV disease pathogenesis. Furthermore, a
creased suppressive function by Bregs.
416 A. von Borstel et al. / Autoimmunity Reviews 17 (2018) 413–421cytokines (reviewed in [46]). In conclusion, Tregs employ multiple
mechanisms to exert their immune suppressive effect and play a pivotal
role in the suppression of autoimmune responses.
2.2. Regulatory T cells in AAV
In AAV defective immune suppression of Tregs may contribute to
persistent immune cell activation and development of chronic autoim-
mune inﬂammation. To date, most research on immune regulation in
AAV has focused on the aberrant function and/or altered frequency of
Tregs. Although most studies agree on the fact that Treg-mediated im-
mune suppression is impaired in AAV, some controversy exists on
whether this defect is caused by numerical or functional changes or
both. These aspects will be discussed in more detail in the next para-
graphs. Key publications on Tregs in AAV are summarized in Table 1.
2.2.1. Numerical and functional alterations of Tregs in AAV
There is somediscrepancy in literature regarding Treg proportions in
AAV: our group previously assessed the frequency of Tregs in peripheral
blood of GPA patients in remission and observed that the frequency of
CD25hiFoxP3+ Tregs was increased in AAV patients compared to HCs
[47], as did others [19,48]. In contrast, others have reported a decreased
CD4+CD25hi Treg frequency in GPA patients [26,49–51]. In one study,
the decrease in the CD4+CD25hi Treg frequency was associated with
the conventional immunosuppressive therapy the patients received
(i.e. CYC + pred or MMF/MTX/AZA + pred) [49]. Interestingly, in the
same study it was observed that the circulating Treg frequency in pa-
tients receiving B cell depletion therapy (i.e. Rituximab (RTX))was sim-
ilar to HCs, whereas it was signiﬁcantly increased compared to
conventionally treated patients [49]. However, in this study, FoxP3 ex-
pression within the CD4+CD25hi T cell compartment was not assessed,
which is important since it identiﬁes activated Tregs as demonstrated
by Miyara et al. [35]. Another study found that the percentage of Tregs
signiﬁcantly expanded during extended remission (≥1 year), indepen-
dently of immunosuppressive treatment. The increase in Treg frequency
was accompanied by an increased Th2 frequency. The authors specu-
lated that decreased Treg numbers in active AAV allow expansion of
Th17 cells during remission, whereas immunosuppressive medication
inhibits Th17 cells and allows Treg expansion resulting in a shift in ThTable 1
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[49]cell balance [26]. Combined, these results indicate that immunosuppres-
sivemedication restores the Treg frequencyof AAVpatients in remission.
Although there is no consensus concerning Treg frequency in AAV,
all studies conducted so far, but one [52], report a reduced suppressive
function of Tregs in the majority of AAV patients [47,48,50,51]. Previ-
ously, our group showed that despite an increased frequency of
FoxP3+ Tregs in GPA patients, their suppressive function was dimin-
ished as demonstrated by increased proliferation of responder T cells
in co-cultures with Tregs from AAV patients [33], which was subse-
quently conﬁrmed by others [48,50,51].
Together, these results indicate that the discrepancy in the literature
with respect to Treg frequencies in AAV patientsmay, at least in part, be
explained by differences in markers or gating strategies used to identify
Tregs between the studies. Nevertheless, most studies agree on the fact
that Treg function is diminished in AAV.2.2.2. Possible underlying causes for Treg malfunctioning in AAV
Although most studies demonstrate diminished suppressive func-
tion of Tregs in AAV patients, the exact mechanisms underlying im-
paired Treg function are unknown. The ﬁrst mechanism that might
induce decreased suppression by Tregs is the apparent plasticity of
these cells in a pro-inﬂammatory microenvironment. Evidence exists
of Tregs converting into Th1 cells in diabetes patients [53,54]. Two stud-
ies involving type 1 diabetes patients showed that Th1-like Tregs
expressed Tbet and CXCR3 besides FoxP3 and produced IFNγ, indicating
that these Tregs lost their suppressive function [53,54]. Interestingly, in
2008 it was demonstrated that CD25hiFoxP3+ T cells could convert into
IL-17-producing T cells when stimulated with allogeneic Ag presenting
cells (APCs) [40]. This observation was later also conﬁrmed by others
[42,55]. Subsequent studies in rheumatoid arthritis (RA) [56] and cancer
[57] demonstrated that Th17-like Tregs expressing FoxP3 were speciﬁ-
cally more abundant at inﬂammatory sites. Also in AAV there seems to
be increased skewing of Tregs towards IL-17-producing cells at sites of
inﬂammation [58], which was hypothesized to be due to increased IL-
6 and TGFβ production in the inﬂammatory microenvironment [59].
These ﬁndings suggest that the impaired suppressive capacity of Tregs
could be due to extensive exposure to TGFβ and IL-6 at inﬂammatory
sites. Such a mechanismmay be operative in AAV as well, given the re-
ported increase in Th17 levels and diminished Treg function in AAV pa-
tients [25]. IL-6 seems to be of great importance as it was recently
demonstrated that Tregs lose their suppressive function, accompanied
by decreased Helios expression, when exposed to IL-6 [60]. Helios is a
TF expressed in Tregs that can be induced in vitro by TGFβ stimulation,
and has previously shown to support suppressive function of Tregs. In-
terestingly, in RA patients treatment with Tocilizumab, a monoclonal
antibody (Ab) blocking the IL-6-receptor, was associated with an in-
creased frequency of circulating Helios+FoxP3+CD4+ T cells compared
to HCs or RA patients that did not receive Tocilizumab [60]. Moreover,
forced Helios expression in murine Tregs enhanced their suppressive
function in conjunction with increased expression of Treg markers (i.e.
CD103, GITR, GARP, FR4 and IL-10) [60]. Collectively, the observations
described above suggest that the plasticity of Tregs may contribute to
an ampliﬁcation loop in autoimmune diseases such as AAV. In AAV a
pro-inﬂammatory environment with high levels of IL-6 converts Tregs
into IL-17-producing T cells, lose their suppressive function and pro-
mote ongoing effector cell activation. Moreover, since these non-
suppressive Th17-like Tregs do express FoxP3, it again emphasizes the
need for additional markers to identify genuine suppressive Tregs.
As a second mechanism, Wilde and colleagues proposed that per-
haps the diminished suppressive capacity of Tregs in AAV is related to
reduced responsiveness to IL-2. They demonstrated signiﬁcantly de-
creased expression of the β-chain of the IL-2 receptor (IL-2R; CD122)
on activated Th cells and Tregs in AAV patients compared to HCs [61].
IL-2 is a cytokine that all T cells need for their functioning under both
homeostatic and inﬂammatory conditions (reviewed in [62]). If Tregs
417A. von Borstel et al. / Autoimmunity Reviews 17 (2018) 413–421are less responsive to IL-2, Tregs possibly cannot exert their suppressive
function.
Aberrant expression in FoxP3-isoforms could be a third explanation
for Treg malfunctioning in AAV. As mentioned before, the FoxP3ﬂ, but
not FoxP3Δ2, interacts with RORγt and inhibits the expression of
genes that deﬁne Th17 cells. Thus, FoxP3Δ2 may result in a dominant
expression of RORγt in Tregs, ensuing production of IL-17 and skewing
of Tregs towards pathogenic Th17 cells. Interestingly, the FoxP3Δ2 iso-
form in Th cells was increased in both active and inactive AAV patients
compared to HCs. In addition, the frequency Tregs with FoxP3ﬂwas de-
creased in the same patients in comparison to HCs. A positive correla-
tion was found between decreased suppressive capacity of Tregs of
AAV patients and the frequency of exon 2-deﬁcient Tregs [48]. Taken to-
gether, these results indicate that expression of the splice variant of
FoxP3 may be responsible for decreased suppressive function.
A fourth explanation focuses on epigenetic aberrancies in Tregs. The
CpGmotifs in the FoxP3 promoter, also called Treg-speciﬁc demethylated
region (TSDR), are usually demethylated which allows transcription of
the FoxP3 gene [63]. In resting conventional T cells the same motifs are
onlyweakly demethylated. Acetylated histones weremore strongly asso-
ciatedwith the FoxP3 promoter in Tregs compared to conventional T cells
[63,64], which might makes the FoxP3 promoter more accessible to RNA
polymerase. This would result in transcription of FoxP3 speciﬁcally in
Tregs and thereby activating their suppressive function. Strikingly, a
study conﬁrmed the existence of an inactive Treg population that lost
both FoxP3 expression and their suppressive function, which was associ-
ated with a demethylated TSDR indicating commitment to the Treg line-
age. Intriguingly, FoxP3 expression, and therewith suppressive function,
could be reinforced via TCR stimulation in these inactive Tregs [65]. Fur-
ther studies are necessary to conﬁrmwhether histones are less acetylated
in AAV, causing increased methylation of the FoxP3 promoter and
resulting in more inactive Tregs.
In summary, several mechanisms have been proposed to mediate
decreased suppressive function of Tregs including IL-6 mediated Treg-
Th17 conversion, reduced IL-2 responsiveness, increased expression of
FoxP3 splice variants and the FoxP3 promotor methylation status. All
of these may be involved in the reported reduced suppressive capacity
of Tregs in AAV as well. However, the exact mechanism of their impair-
ment in AAV remains to be determined.
3. B cell involvement in AAV
B cells play an important role in the pathogenesis of AAV as they are
the precursors of plasma cells that produce ANCA. However, B cells
exert multiple other functions including Ag presentation and produc-
tion of a variety of pro- and anti-inﬂammatory cytokines. These proper-
ties of B cells suggest that these cells may contribute to the pathogenic
and immune regulatory processes in AAV in anAb-independentmanner
as well [66,67].
Evidence for an Ab-independent pathogenic role of B cells in AAV
was ﬁrst described in 1999. In this study it was shown that the fre-
quency of activated B cells, identiﬁed as B cells with high expression
levels of CD38, was signiﬁcantly increased during active disease com-
pared to patients in remission andHCs [68]. Interestingly, no correlation
between activated B cells and ANCA levels was found, whereas the pro-
portion of activated B cells did signiﬁcantly correlatewith disease activ-
ity [68].
Additional evidence for an Ab-independent role of B cells in AAV
comes from two major clinical trials that demonstrated that treatment
with the B cell-depleting Ab RTX is as efﬁcacious in inducing disease re-
mission in AAV as standard immunosuppressive therapy [66,67]. RTX is
a chimeric monoclonal anti-CD20 Ab that depletes B- but not plasma
cells. Upon RTX treatment, ANCA in the circulation were detectable in
patients in remission and only decreased after six months after start of
RTX treatment [66,67], indicating that clinical improvement in RTX-
treated patients can precede the reduction in autoAb titers. Moreover,relapses did occur in RTX-treated AAV patients, but only after B cell re-
population [67]. This indicates that besides eliminating the precursors
of Ab-generating cells, the therapeutic effects of RTX also involve mod-
ulation of Ab-independent properties of B cells.
The Ab-independent functions of B cells and their potential role in
autoimmune disease pathogenesis have gained considerable interest
in recent years. In particular, the fact that B cells can produce pro- and
anti-inﬂammatory cytokines that can shape both T cell and innate im-
mune responses and act as drivers or regulators of (auto)immune re-
sponses respectively, is increasingly recognized [69]. Moreover, in
mice and humans speciﬁc B cell subsets termed Bregs, have been iden-
tiﬁed that display immune regulatory properties. Bregs are deﬁned by
their capacity to suppress pathological immunity primarily via provi-
sion of IL-10 and in mouse models of various autoimmune disorders
IL-10-producing B cells have been shown to suppress disease develop-
ment [15,70]. This has led to the concept that in autoimmune disorders
such as AAV, the balance between B effector cells and Bregs may be dis-
turbed, driving the pathological autoimmune response.
3.1. Regulatory B cells: Phenotype and mechanism of action
The theory that B cells are able to suppress immune responses was
ﬁrst postulated by both Katz and Neta in 1974 [71,72]. They showed
that adoptive transfer of B cell-depleted splenocytes were unable to
suppress delayed type hypersensitivity in guinea pigs, which suggested
that B cellsmay suppress the activity of T cells in delayed skin hypersen-
sitivity. However, the phenotype and the mechanism of action of these
suppressor B cells remained uncharacterized. In 2002, studies in animal
models of colitis and experimental autoimmune encephalitis (EAE)
showed that a subset of B cells could suppress inﬂammation and that
IL-10 is a hallmark of these suppressive B cells [15,73]. In 2008, Yanaba
and coworkers reintroduced the paradigm of suppressor B cells in mice
by identifying a subset of peripheral B cells expressing surface CD5 and a
high level of CD1d, whichwere termed Bregs [74]. Bregswere also iden-
tiﬁed in humans and characterized by the production of IL-10 upon
in vitro stimulation [75,76]. Since in vitro identiﬁcation of human Bregs
via IL-10 is labor intensive (i.e. PBMC isolation and cell culture is needed),
there was a clear need for immunophenotypical surface markers that
classify Bregs. The search for a speciﬁc Breg immunophenotype has so
far led to multiple studies that claimed to have identiﬁed (different)
Breg-speciﬁc markers [75–78].
Firstly, Bregs have been identiﬁed in the immature or transitional B
cell subset [75]. These Bregs were characterized by high expression of
both CD24 and CD38. Flores-Borja et al. showed that this CD24hiCD38hi
Breg subset successfully inhibited the differentiation of naïve T cells into
both Th1 and Th17 cells. Production of IL-10 was mainly found in the
CD24hiCD38hi Breg compartment, and these Bregswere potent suppres-
sors of multiple activated cell types and played an important role in ac-
tivating Tregs [79]. Additional surfacemarkers have been reported to be
expressed by immature Bregs to identify truly suppressive Bregs that in-
clude CD1d [78] and CD5 [75]. However, the exact phenotype by which
suppressor CD24hiCD38hi Bregs can be recognized is not yet elucidated.
In addition to the immature/transitional Bregs, a second Breg subset
was identiﬁed within the CD27+ memory B cell compartment [76].
These memory CD24hiCD27+ Bregs were also enriched for IL-10 pro-
duction and suppressed cytokine production in CD4+ T cells in vitro
[76]. It seems that the immunosuppressive property of Bregs is mainly
mediated via IL-10 secretion (Fig. 1).
In addition to IL-10, studies have shown that activated Bregs can ex-
press other immune regulatory cytokines including IL-35 and TGFβ.
Studies in EAE mice showed that B cells lacking IL-35 expression medi-
ated exacerbated EAE and thesemice lost the ability to recover from the
disease [80]. Another study demonstrated that adoptive transfer of IL-
35-producing Bregs inhibited experimental uveitis [81]. It has also
been shown that B cells down-regulate pathogenic autoimmune re-
sponses via expression of TGFβ [82]. Treatment of prediabetic non-
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spontaneous T cell autoreactivity to β cell autoAgs, enhanced mononu-
clear cell apoptosis in the peripheral lymphoid tissue, and temporarily
impaired the function of APCs. TGFβ-secreting Bregs have also been
identiﬁed in humans, where this subset was characterized by high ex-
pression of CD25, a signature marker of Tregs. TGFβ produced by
these Bregs promoted FoxP3 and CTLA-4 expression in T cells [83].
All the aforementioned ﬁndings demonstrate that Bregs mediate
their suppressive effect through the expression of immune regulatory
cytokines. In addition to expression of immunomodulatory cytokines,
a new cytotoxic marker in Bregs was identiﬁed: granzyme B (GzmB)
production [77]. GzmB production by these Bregs seems to be an addi-
tionalmechanismof Breg-mediated suppression to exert their cytotoxic
activity.
Besides the secretion of cytokines and cytotoxic proteins, Bregs need
direct cell-cell interaction to suppress other immune cells. It was shown
that direct cell-cell contact of Bregs with T cells, mediated via CD40-
CD40L interaction, was a crucial pathway for IL-10 induction in B cells
and also induced CTLA-4 and FoxP3 expression in T cells [15]. Interest-
ingly, IL-10 production by Bregs also impacts the suppressive function
by Tregs. It has been shown that Tregs lacking the IL-10 receptor do
not suppress activated Th17 cells [84], indicating that IL-10 signaling
in Tregs is crucial formaintaining certain immunosuppressive functions
of this subset. This could be an additional mechanism of Bregs bywhich
they impact the suppressive function of Tregs.
Altogether, Bregs play an important role in suppressing immune re-
sponses and multiple mechanisms of suppression have been demon-
strated. Besides IL-10, Bregs can exert their suppressive function via
TGFβ- and IL-35 secretion and the expression of cytotoxic proteins.Mul-
tiple studies clearly show that Bregs are needed for both the suppres-
sion of activated immune cells and induction of differentiation of
naïve cells into regulatory cells. However, more research is needed to
clarify the exact underlying mechanism for each Breg subset.
3.2. Regulatory B cells in AAV
Studies involving Bregs in autoimmune diseases have focused pre-
dominantly on abnormalities in their numbers (based on their surface
markers) and/or function (based on in vitro IL-10 expression and sup-
pression of immune cells in co-culture). In this section we will review
studies on Bregs in AAV. Key publications on B cell suppression in AAV
are summarized in Table 2.
Using the phenotypicalmarkers CD24 and CD38 to distinguish circu-
lating Bregs, contradictory results were found in patients with AAV. The
study by Todd and coworkers demonstrated a signiﬁcant reduction in
the frequency of circulating immature CD24hiCD38hi Bregs in both
MPO- and PR3-AAV patients with quiescent disease, whereas during ac-
tive disease only in PR3-AAV patients a decreased Breg frequency was
found [85]. Another study by Aybar and coworkers showed that theTable 2
Key publications on Bregs in AAV.
Authors, journal &
year
Patients Breg subset studied
O'Dell Bunch et al.
Ann. Rheum. Dis. (2013)
PR3- & MPO-AAV CD5+ B cells
Wilde et al.
Ann. Rheum. Dis. (2013)
PR3- & MPO-AAV IL-10+ B cells
Lepse et al.
Rheumatology (2014)
PR3- & MPO-AAV CD24hiCD38hi & CD24hiCD27+ Br
Todd et al.
Rheumatology (2014)
GPA & MPA CD24hiCD38hi Bregs
Aybar et al.
Clin. Exp. Immunol. (2015)
PR3- & MPO-AAV CD5+CD24hiCD38hi Bregs
Unizony et al.
Arthr. Rheum. (2015)
AAV CD5+ B cellsfrequency of circulating CD24hiCD38hi Bregs, additionally deﬁned by
CD5, was decreased during active AAV and normalized during disease
remission [86]. In accordance we found a decreased frequency of circu-
lating CD24hiCD38hi Bregs in GPA patients with active disease, whereas
no difference was observed in quiescent patients in comparison to HCs
[87]. In addition we analyzed the frequency of memory CD24hiCD27+
Bregs and we found a signiﬁcant decrease in the frequency of these
memory Bregs in both active and quiescent AAV patients compared to
HCs [87]. Overall, all studies indicate a reduction in circulating Breg fre-
quency during active AAV, which highlights their role in disease
progression.
To further evaluate the relationship between Bregs and states of re-
mission and relapse in AAV, O'Dell Bunch and colleagues examined cir-
culating Bregs (identiﬁed by CD5 expression) in AAV patients that
received RTX and consequently underwent B cell depletion [88]. They
found that these Bregs were decreased during active disease, and nor-
malized during remission. A signiﬁcant shorter time to relapse (i.e.
17months)was observed in patientswith lowCD5+ B cell repopulation
(i.e. b30%) after treatment with RTX combined with a low dose (i.e.
b1 g/day) mycophenolate mofetil (MMF). In contrast, in patients with
N30% CD5+ B cell repopulation an increased time to relapse (i.e.
31 months) was found [88,89]. Moreover, an inverse correlation was
found between the percentage of CD5+ B cells and disease activity in
RTX-treated patients only. These results indicate that Bregs are protec-
tive in AAV patients. Contrastingly, in the study by Unizony and co-
workers no relation was found between the percentage CD5+ B cells
and relapse rate [90]. Further studies are needed to clarify whether
Bregs identiﬁed by CD5 expression are protective for disease relapses
in AAV and how the frequency of these cells is inﬂuenced by treatment.
As IL-10 is considered the functional marker of Bregs, studies have
analyzed the frequency of IL-10-producing Bregs upon in vitro stimula-
tion. In AAV, multiple groups have studied the frequency of IL-10-
producing Bregs after in vitro stimulation. One study showed that the
IL-10+ B cell frequency was decreased in active and remission AAV pa-
tients compared to HCs [91]. Interestingly, others only found a de-
creased IL-10+ B cell frequency in active patients and a normal
frequency in remission patients [86]. Contrastingly, we and others
found no difference in the IL-10+ B cell frequency in AAV patients com-
pared to HCs [85,87]. Together these results show that there is no con-
sensus yet about the IL-10+ B cell frequency in AAV and more
research should focus on these cells in AAV.
Asmentioned before, Bregs can also exert their suppressive function
by producing other immunomodulatory cytokines, such as IL-35 and
TGFβ, and the cytotoxic protein GzmB. Notmuch knowledge is available
about the expression of IL-35 and TGFβ in Bregs from AAV patients. In a
preliminary study, a decrease in GzmB production was found in B cells
derived fromquiescent AAV patients after in vitro stimulation compared
to HCs [92], suggesting that cytotoxic Breg function is decreased in AAV
patients.Main conclusion Reference
A decreased CD5+ B cell frequency after B cell depletion
shortens the time to relapse in AAV.
[88]
IL-10 producing B cells are diminished in AAV. [91]
egs In AAV, the B cell balance is altered, but B cell function is
not impaired reﬂected as the inhibition of TNFα production
from monocytes.
[87]
Regulatory B cells are numerically but not functionally
deﬁcient in AAV.
[85]
Reduced CD5+CD24hiCD38hi and IL-10+ regulatory B cells
in active AAV permit increased circulating autoAbs.
[86]
The percentage CD5+ B cells correlates inversely with
disease activity after RTX therapy.
[90]
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cytokine pattern, researchers have also assessed their suppressive ca-
pacity in vitro. Interestingly, no deﬁciency in Breg suppressive function
was found so far in AAV. One study co-cultured CD24hiCD38hi Bregs
and CD4+ T cells and found signiﬁcant suppression when cultured in a
1:1 ratio. The CD24hiCD38hi Bregs from AAV patients prevented both
TNFα- and IFNγ production by T cells to the same extent as the same
Bregs from HCs did [85]. We previously co-cultured total CD19+ B
cells with monocytes (1:1 ratio) and activated the B cells with CpG
and CD40L and monocytes with LPS. We showed that the inhibition of
monocyte TNFα production by AAV Bregs was not different from HCs
Bregs since the same frequencies of TNFαwere found [87]. Both studies
indicate that Bregs from AAV patients are not inferior in suppressing
pro-inﬂammatory cytokine production in both T cells and monocytes.
Overall, the available data described here indicate that an imbalance
between regulatory and effector functions of B cells is an important as-
pect contributing to disease pathogenesis in AAV (Fig. 1). Decreased
Breg numbers were most prominent in patients with active disease,
which may contribute to decreased immune suppression in AAV pa-
tients. However, to date there is no evidence for impaired Breg function-
ing in AAV.
4. Concluding remarks
In AAV patients elimination or adequate suppression of autoreactive
T- and B cells fails. This allows initiation and propagation of the immune
response against self-proteins leading to the development of
autoreactive effector T cells and pathogenic autoAb production. To
date, multiple studies in AAV focusing on the immune regulatory cell
types essential for peripheral tolerance (i.e. Tregs and Bregs) have dem-
onstrated numerical and functional aberrations in these immune regu-
latory subsets, although discrepancies between studies exist. For
Tregs, data on numerical changes in AAV patients are inconsistent but
inmost studies the suppressive function of Tregswas found to bedimin-
ished. For Bregs, decreased numbers of this subset in AAV patients have
been described but so far no deﬁciencies in suppressive function have
been reported. Collectively, these data indicate that a dysbalance be-
tween effector and regulatory cells in both the T- and B cell compart-
ment is an important aspect of AAV pathogenesis suggesting that
(therapeutic) ways of restoring this balance could be of beneﬁt for
AAV patients.
However, many questions still remain. First, it is currently unknown
whether the observed aberrations in immune regulatory subsets are a
cause or consequence of the disease and relatively little attention has
been paid to the (long-term) effects of induction andmaintenance ther-
apy on these subsets. Second, further clariﬁcation of the phenotypes of
both Bregs and Tregs is needed. For Bregs, multiple markers are cur-
rently used to deﬁne these cells and this has led to the description of
multiple Breg subsets. Although a more discriminative phenotype
would enable more accurate elucidation of the role of Bregs in AAV, it
is also likely that immunosuppression in the B cell compartment is not
a trait of a separate Breg lineage with a speciﬁc phenotype. As proposed
by Mauri and colleagues, immunosuppression by B cells could also
rather be the outcome of the dynamic balance between multiple B cell
subsets and other cells of the immune system suggesting that Bregs
emerge as a consequence of the inﬂammatory responsewhen immuno-
suppression is most needed [93]. Regarding Tregs, the challenge will be
to ﬁndmarkers that speciﬁcally delineate true suppressive Tregs. Third,
little is known about the underlying mechanisms that mediate de-
creased suppressive function of Tregs in AAV. In AAV patients there
are indications that the proportion of Tregs expressing a FoxP3-
isoform that inhibits their suppressive ability is increased. It may be
worthwhile to perform more detailed studies on the expression of
genes potentially contributing to diminished suppressive function of
Tregs by for example (single cell) RNA sequencing. Such studies might
reveal differentially regulated genes in Tregs of AAV patients. Inconjunction with functional analyses of these genes, such studies may
pinpoint important mechanisms contributing to the functional impair-
ment of Tregs in AAV and potentially identify targets amenable for ther-
apeutic intervention.Disclosure
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